McMaster University are set to begin human trials for a pair inhaled COVID-19 vaccines designed to combat variants of concern.Unlike current vaccines available now, the new generation aerosol will target the lungs and upper airways, where respiratory infections begin.“We’ve developed a COVID vaccine that contains three of the proteins of COVID-19.
The novel part of our vaccine is not only the part around the development of the vaccine cells, but the administration of it,” microbiologist Dr.
Fiona Smaill said in a release. Canadian manufacturer Medicago’s COVID-19 vaccine showing strong efficacy “That’s probably the most exciting part.